Literature DB >> 27841981

Clinically Significant Drug-Drug Interactions Between Hepatitis C Virus and HIV Treatments.

Jennifer J Kiser1.   

Abstract

The potential for drug-drug interactions is an important consideration in the treatment of HIV/hepatitis C virus (HCV) coinfection. Regimens for HCV genotype 1 infection are discussed in the context of an individual on stable antiretroviral therapy, to determine which HCV treatments may be initiated without requiring a change in antiretroviral regimen or an increase in monitoring for potential drug-drug interactions. The effects of potential interactions between HCV drugs and other therapeutic classes of drugs are also discussed. This article summarizes a presentation by Jennifer J. Kiser, PharmD, at the IAS-USA continuing education program, Improving the Management of HIV Disease, held in Los Angeles, California, in April 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27841981      PMCID: PMC6148915     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  4 in total

1.  A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting: The Annual Meeting of the European Association for the Study of the Liver • April 13-17, 2016 • Barcelona, SpainSpecial Reporting on:• Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) Are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The HepNet Acute HCV IV Study• Treatment of Hepatitis C Virus in Patients With Advanced Cirrhosis: Always Justified? Analysis of the HEPA-C Registry• High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 in Previously Treated Patients With HCV Genotypes 1 Through 6• Prevalence and Impact of Baseline Resistance-Associated Variants (RAVs) on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis• Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study• 100% SVR12 With ABT-493 and ABT-530 With or Without Ribavirin in Treatment-Naive HCV Genotype 3-Infected Patients With CirrhosisPLUS Meeting Abstract SummariesWith Expert Commentary by:Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-06

2.  Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.

Authors:  Elliot B Tapper; Bruce R Bacon; Michael P Curry; Douglas T Dieterich; Steven L Flamm; Lauren E Guest; Kris V Kowdley; Yoori Lee; Naoky C Tsai; Zobair M Younossi; Nezam H Afdhal
Journal:  Hepatology       Date:  2016-10-05       Impact factor: 17.425

3.  Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.

Authors:  Amit Khatri; Sandeep Dutta; Martin Dunbar; Thomas Podsadecki; Roger Trinh; Walid Awni; Rajeev Menon
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.

Authors:  Julie C Lauffenburger; Christina L Mayer; Roy L Hawke; Kim L R Brouwer; Michael W Fried; Joel F Farley
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-10       Impact factor: 2.566

  4 in total
  3 in total

1.  Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort.

Authors:  Miriam Coghlan; Aisling O'Leary; Gail Melanophy; Colm Bergin; Suzanne Norris
Journal:  Int J Clin Pharm       Date:  2019-07-11

2.  Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus.

Authors:  Luis Margusino-Framiñán; Purificación Cid-Silva; Victor Giménez-Arufe; Cristina Mondelo-García; Carla Fernández-Oliveira; Álvaro Mena-de-Cea; Isabel Martín-Herranz; Ángeles Castro-Iglesias
Journal:  Eur J Hosp Pharm       Date:  2019-06-13

Review 3.  Drug-Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives.

Authors:  Nicolas Cottura; Hannah Kinvig; Sandra Grañana-Castillo; Adam Wood; Marco Siccardi
Journal:  J Clin Pharmacol       Date:  2022-02-08       Impact factor: 2.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.